(Q46215056)

English

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

scientific article published in October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

hypercholesterolemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

11

object named as

G Kees Hovingh

0 references

author name string

Frederick J Raal

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Evan A Stein

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Robert Dufour

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Traci Turner

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Fernando Civeira

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Lesley Burgess

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Gisle Langslet

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Russell Scott

8

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Anders G Olsson

9

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

David Sullivan

10

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

G Kees Hovingh

11

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Bertrand Cariou

12

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Ioanna Gouni-Berthold

13

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Ransi Somaratne

14

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Ian Bridges

15

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Rob Scott

16

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Scott M Wasserman

17

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Daniel Gaudet

18

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

RUTHERFORD-2 Investigators

19

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

language of work or name

0 references

publication date

1 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

385

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

9965

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

331-340

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial hypercholesterolemia and coronary heart disease: a HuGE association review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961399-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)61399-4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/25282519

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46215056&oldid=2100055673"